| 2,165 | 12 | 58 |
| 下载次数 | 被引频次 | 阅读次数 |
脂肪肝是由多种因素导致的肝细胞内大量脂肪堆积从而引起肝脏病理性改变的代谢性疾病。近年来，随着生活水平的提高及饮食结构的变化，脂肪肝发病率有逐渐增加的趋势，对人们的健康造成了严重威胁。中药在脂肪肝的防治方面有着显著的效果，且具有多成分、多途径和多靶点的特点，已成为该领域近年来的研究热点。大量研究表明大黄具有降脂、保肝护肝作用。然其相关成分及作用机制尚不完全清晰，故本文通过对大黄成分及其治疗脂肪肝的中英文文献进行系统分析，结果显示，大黄治疗脂肪肝的主要活性成分为大黄素、大黄酚、大黄酸等，其机制至少包括修复肝细胞损伤、减轻炎症反应、减轻氧化应激、调控脂质代谢、改善胰岛素抵抗等，可为大黄的进一步研究和应用提供思路和参考。
Abstract：Fatty liver is a metabolic disease caused by a large amount of fat accumulation in liver cells caused by various factors, which leads to pathological changes in the liver. In recent years, with the improvement of living standards and changes in dietary structure, the incidence of fatty liver has gradually increased, which poses a serious threat to people's health. Traditional Chinese medicine has a remarkable effect on the prevention and treatment of fatty liver and has the characteristics of multi-component, multi-pathway, and multi-target, which has become a research hotspot in this field in recent years. A large number of studies have shown that Dahuang(大黄) has lipid-lowering and hepatoprotective effects. However, its related components and mechanism of action are not completely clarified. Therefore, this paper systematically analyzed the components of Dahuang and its treatment of fatty liver in Chinese and English literature. The results show that the main active components of Dahuang in the treatment of fatty liver are emodin, chrysophanol, rhein, etc. The mechanism includes repairing liver cell injury, reducing inflammatory response, reducing oxidative stress, regulating lipid metabolism, and improving insulin resistance, which can provide ideas and references for further research and application of Dahuang.
[1]Mancina R M,Sasidharan K,Lindblom A,et al.PSD3 downregulation confers protection against fatty liver disease[J].Nat Metab,2022,4(1):60-75.
[2]Yki-J?rvinen H,Luukkonen P K,Hodson L,et al.Dietary carbohydrates and fats in nonalcoholic fatty liver disease[J].Nat Rev Gastro Hepat,2021,18(11):770-786.
[3]Zou B,Odden M C,Nguyen M H,et al.Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease[J].Clin Gastroenterol H,2023,21(2):435-44.e6.
[4]Powell E E,WONG V,Rinella M.Non-alcoholic fatty liver disease[J].Lancet,2021,397(10290):2212-2224.
[5]Riazi K,Azhari H,Charette J H,et al.The prevalence and incidence of NAFLD worldwide:a systematic review and meta-analysis[J].Lancet Gastroenterol Hepatol,2022,7(9):851-861.
[6]燕声.近三成国人有脂肪肝[N].保健时报，2023-03-02(4).
[7]万成怡，张斌，朱晓骏.张斌从虚、痰、瘀论治肝癖经验浅析[J].辽宁中医杂志，2023,50(4):25-28.
[8]韦柳婷，胡振斌，高松林，等.中医药治疗非酒精性脂肪肝病的研究进展[J].大众科技，2023,25(3):85-88,84.
[9]钟赣生，杨柏灿.中药学[M].北京：中国中医药出版社，2021:139.
[10]袁建芬，张谈，陆新烈，等.大黄酸治疗非酒精性脂肪性肝炎实验研究[J].山东中医杂志，2013,32(10):746-749.
[11]岑柏春，张谈，袁建芬，等.大黄酸对高脂饮食诱导的大鼠非酒精性脂肪性肝病的防治作用[J].中华中医药学刊，2013,31(3):545-547,709.
[12]吕媛琳，刘晨晨，刘慧，等.大黄酸对非酒精性脂肪肝病模型大鼠干预作用及对血清IL-1β、IL-6的影响[J].浙江中西医结合杂志，2018,28(3):180-183,258.
[13]林晓平，余立华.大黄酸对小鼠非酒精性脂肪肝病的治疗效果分析[J].中国临床医学，2021,28(1):106-110.
[14]张亚辉.大黄素对非酒精性脂肪肝大鼠胰岛素抵抗及瘦素作用的实验研究[D].长沙：中南大学，2010.
[15]张亚辉，周伏喜，卢放根.大黄素对大鼠非酒精性脂肪肝及其糖脂代谢紊乱的防治作用[J].海南医学，2013,24(5):636-638.
[16]吴双成.基于FXR通路探讨大黄素对高脂饮食诱导非酒精性脂肪肝的保护作用[D].广州：广州中医药大学，2021.
[17]王少杰，李晓洁，徐志猛，等.大黄素对小鼠急性脂肪肝的改善作用[J].中国药科大学学报，2017,48(1):89-95.
[18]薛继华，谢琴秀，程君，等.大黄素对刀豆蛋白诱导小鼠急性肝损伤的干预作用及其机制[J].山东医药，2019,59(8):9-12.
[19]阎林奇.大黄素及其固体分散体对大鼠酒精性肝损伤干预作用的研究[D].唐山：河北联合大学，2011.
[20]DONG H,LU F E,GAO Z Q,et al.Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw[J].World J Gastroentero,2005,11(9):1339-1344.
[21]孙晓琦.大黄素对非酒精性脂肪肝小鼠脂质沉积的影响及机理研究[D].南京：南京中医药大学，2011.
[22]余琳媛，龚莉虹，汤韵秋，等.基于AMPK信号通路的大黄素治疗非酒精性脂肪肝病研究进展[J].中国实验方剂学杂志，2020,26(2):203-209.
[23]WANG S J,LI X J,GUO H L,et al.Emodin alleviates hepatic steatosis by inhibiting sterol regulatory element binding protein 1 activity by way of the calcium/calmodulin-dependent kinase kinase-AMP-activated protein kinase-mechanistic target of rapamycin-p70 ribosomal S6 kinase signaling pathway[J].Hepatol Res,2017,47(7):683-701.
[24]WU C,BIAN Y Q,LU B J,et al.Rhubarb free anthraquinones improved mice nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome[J].J Transl Med,2022,20(1):294.
[25]凌霄，李春晓，赵娅等.生、熟大黄对湿热泄泻大鼠炎性细胞因子、胃肠激素与肠道菌群的影响[J].中华中医药学刊，2023,41(11):53-57,266-267.
[26]韩思琪，哈伟，师彦平.大黄及其有效成分抗炎作用的研究进展[J].中草药，2023,54(1):303-316.
[27]武婵娟，薛宁宁，贾红岩.基于“成分-效应”机制探究抗小儿药物渗出方中大黄炮制前后抗炎作用[J].中药材，2022,45(11):2603-2606.
[28]曹强，郭亚菲，叶蕾蕾，等.大黄及其活性成分抗炎作用及机制的研究进展[J].中草药，2022,53(22):7285-7294.
[29]胡云芝，李军民，鲁之中，等.大黄酚对高脂饮食诱导的幼龄大鼠非酒精性脂肪肝的调节作用[J].免疫学杂志，2018,34(10):869-874.
[30]柯辛格.丹叶大黄素对非酒精性脂肪肝的药理作用及机制研究[D].武汉：湖北中医药大学，2021.
[31]YU H,LIN L B,ZHANG Z Q,et al.Targeting NF-κB pathway for the therapy of diseases:mechanism and clinical study[J].Signal transduction and targeted therapy,2020,5(1):209.
[32]姚婷新.大黄素对非酒精性脂肪肝大鼠内毒素性肝损伤的影响[D].长沙：中南大学，2011.
[33]刘涛，徐秋玲，赵岩.大黄素抑制NAFLD大鼠肝脏TLR4信号表达的研究[J].中药新药与临床药理，2016,27(2):201-205.
[34]LI X Q,SHAN C,WU Z H,et al.Correction to:Emodin alleviated pulmonary inflammation in rats with LPS-induced acute lung injury through inhibiting the mTOR/HIF-1α/VEGF signaling pathway[J].Inflammation research :official journal of the European Histamine Research Society,2020,69(7):711.
[35]祁红.大黄素的抗炎作用[J].中草药，1999,(7):522-524.
[36]王硕，吴华，李金铭，等.天然提取物在影响动物氧化应激中的研究进展[J].饲料研究，2023,46(18):145-149.
[37]CHEN Z,TIAN R F,SHE Z G,et al.Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease[J].Free radical biology & medicine,2020,152:116-141.
[38]ZHAO W J,BIAN Y P,WANG Q H,et al.Blueberry-derived exosomes-like nanoparticles ameliorate nonalcoholic fatty liver disease by attenuating mitochondrial oxidative stress[J].Acta pharmacologica Sinica,2022,43(3):645-658.
[39]Kim M H,Seong J B,Huh J W,et al.Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling[J].Redox biology,2020,28:101315.
[40]ABULIKEMU A,ZHAO X Y,XU H L,et al.Silica nanoparticles aggravated the metabolic associated fatty liver disease through disturbed amino acid and lipid metabolisms-mediated oxidative stress[J].Redox biology,2023,59:102569.
[41]丁艳，徐芳，熊小丽，等.法尼醇X受体在急性淤胆型肝炎大鼠模型中的表达及大黄素的干预作用[J].中国当代儿科杂志，2014,16(4):424-429.
[42]张昊悦，赵蓓，王业皇，等.大黄素通过调节Nrf2/HO-1和MAPKs抑制炎症和氧化应激机制研究[J].中国免疫学杂志，2021,37(9):1063-1068.
[43]刘鸣昊，张丽慧，马庆亮，等.大黄素对非酒精性脂肪性肝炎模型大鼠作用及对脂联素、脂联素受体的影响[J].中华中医药学刊，2020,38(2):187-190,290.
[44]张征波.大黄素对非酒精性脂肪肝单纯肝脂肪变性改善作用及机制研究[D].南京：南京中医药大学，2012.
[45]ZHUANG S,YU R Y,ZHONG J,et al.Rhein from Rheum rhabarbarum Inhibits Hydrogen-Peroxide-Induced Oxidative Stress in Intestinal Epithelial Cells Partly through PI3K/Akt-Mediated Nrf2/HO-1 Pathways[J].Journal of agricultural and food chemistry,2019,67(9):2519-2529.
[46]陈书雅，倪安煜，钱秋慧，等.N～6-腺苷酸甲基化修饰在脂质代谢紊乱疾病中调控作用研究进展[J].生理学报，2023,75(3):439-450.
[47]ZHAO M,BU Y A,FENG J Y,et al.SPIN1 triggers abnormal lipid metabolism and enhances tumor growth in liver cancer[J].Cancer letters,2020,470:54-63.
[48]LIU X Z,WANG L F,TAN S W,et al.Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora[J].Frontiers in pharmacology,2022,13:814871.
[49]Huh J Y,Saltiel A R.Roles of IκB kinases and TANK-binding kinase 1 in hepatic lipid metabolism and nonalcoholic fatty liver disease[J].Experimental & molecular medicine,2021,53(11):1697-1705.
[50]SU D,LIAO Z,FENG B W,et al.Pulsatilla chinensis saponins cause liver injury through interfering ceramide/sphingomyelin balance that promotes lipid metabolism dysregulation and apoptosis[J].Phytomedicine :international journal of phytotherapy and phytopharmacology,2020,76:153265.
[51]Loomba R,Friedman S L,Shulman G I.Mechanisms and disease consequences of nonalcoholic fatty liver disease[J].Cell,2021,184(10):2537-2564.
[52]姚静，刘翠玲，孙辉，等.霍山石斛鲜品对慢性酒精性肝损伤小鼠的保护作用研究[J].中药新药与临床药理，2023,34(6):764-770.
[53]董慧，陆付耳，高志强，等.大黄素对酒精和高脂饲养诱导的大鼠脂肪肝的影响[J].中国医院药学杂志，2005,(3):202-204.
[54]周伏喜.大黄素对非酒精性脂肪肝大鼠的干预作用及可能机制研究[D].长沙：中南大学，2011.
[55]匡双玉.基于治疗NAFLD的三味中药及有效成分的活性研究[D].长沙：湖南中医药大学，2014.
[56]刘涛，徐秋玲，赵岩，等.大黄素对非酒精性脂肪肝大鼠脂质水平及肝脏脂质代谢基因表达的影响[J].中草药，2010,41(9):1516-1518.
[57]Smith G I,Shankaran M,Yoshino M,et al.Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease[J].The Journal of clinical investigation,2020,130(3):1453-1460.
[58]Khan R S,Bril F,Cusi K,et al.Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease[J].Hepatology (Baltimore,Md),2019,70(2):711-724.
[59]Meex R C R,Watt M J.Hepatokines:linking nonalcoholic fatty liver disease and insulin resistance[J].Nature reviews Endocrinology,2017,13(9):509-520.
[60]孙红爽，李鹏霖，刘永双，等.大黄素对大鼠非酒精性脂肪肝及肝组织11β-羟基类固醇脱氢酶1表达的影响[J].实验动物科学，2022,39(3):22-26,32.
[61]MA C R,WANG Z Y,XIA R L,et al.Danthron ameliorates obesity and MAFLD through activating the interplay between PPARα/RXRα heterodimer and adiponectin receptor 2[J].Biomed Pharmacother,2021,137:111344.
[62]Alisi,A,Pastore A,Ceccarelli S,et al.Emodin prevents intrahepatic fat accumulation,inflammation and redox status imbalance during diet-induced hepatosteatosis in rats[J].Int J Mol Sci,2012,13(2):2276-2289.
[63]徐在品，卢占军，陈眷华，等.大黄醇提液抗家兔实验性高脂血症及脂肪肝的实验研究[J].中国应用生理学杂志，2007,(3):375-380.
[64]周利玲，舒筱灿，吴和平，等.大黄素干预鹌鹑脂肪肝病变的效果[J].中国临床康复，2006,(32):57-59,197.
[65]LI X J,XU Z M,WANG S J,et al.Emodin ameliorates hepatic steatosis through endoplasmic reticulum-stress sterol regulatory element-binding protein 1c pathway in liquid fructose-feeding rats[J].Hepatol Res,2016,46(3):E105-E117.
[66]杨以琳，潘竞锵，吕俊华，等.大黄提取物治疗高糖-高脂诱导大鼠非酒精性脂肪性肝病作用及机制[J].广州医药，2012,43(4):38-43.
[67]董慧，陆付耳，高志强，等.大黄素治疗高脂饮食诱发的大鼠非酒精性脂肪肝的实验研究[J].中国中西医结合杂志，2006,(S1):64-67.
[68]陆新烈，袁建芬，徐建立，等.大黄酸对非酒精性脂肪性肝病大鼠肝脏病理组织学及超微结构变化的影响[J].中国中医药科技，2013,20(5):477-478.
[69]SHENG X Y,WANG M,LU M,et al.Rhein ameliorates fatty liver disease through negative energy balance,hepatic lipogenic regulation,and immunomodulation in diet-induced obese mice[J].American journal of physiology Endocrinology and metabolism,2011,300(5):E886-E893.
[70]张征波，薛博瑜.大黄素对非酒精性脂肪肝小鼠肝脂质沉积的作用及机制[J].中华中医药杂志，2012,27(9):2423-2425.
[71]YANG M X,LI X M,ZENG X,et al.Rheum palmatum L.Attenuates High Fat Diet-Induced Hepatosteatosis by Activating AMP-Activated Protein Kinase[J].Am J Chinese Med,2016,44(3):551-564.
[72]尹春梅.大黄素、小檗碱对HepG2细胞瘦素受体mRNA表达影响的实验研究[D].太原：山西医科大学，2009.
[73]尹春梅，王琦，王慧莲.大黄素和小檗碱对高浓度瘦素作用下HepG2细胞瘦素受体mRNA表达的影响[J].世界华人消化杂志，2009,17(11):1122-1125.
[74]LIU Y,CHEN X L,QIU M C,et al.Emodin ameliorates ethanol-induced fatty liver injury in mice[J].Pharmacology,2014,94:71-77.
[75]Raal A,Pokk P,Arend A,et al.Trans-resveratrol alone and hydroxystilbenes of rhubarb (Rheum rhaponticum L.) root reduce liver damage induced by chronic ethanol administration:a comparative study in mice[J].Phytother Res :PTR,2009,23(4):525-532.
基本信息:
DOI：10.13412/j.cnki.zyyl.20240420.001
中图分类号:R285
引用信息:
[1]杨宗慧,陈红刚,赵文龙,等.大黄及有效成分治疗脂肪肝作用机制的研究进展[J].中药药理与临床,2025,41(07):113-120.DOI:10.13412/j.cnki.zyyl.20240420.001.
基金信息:
中国工程院院地合作重大项目(编号：GS2021ZDA06); 甘肃省自然科学基金项目(编号：20JR10RA330); 甘肃省道地药材质量标准化技术研究与推广工程实验室开放基金项目(编号：ddyc-2022-02); 甘肃省中药药理与毒理学重点实验室开放基金项目(编号：ZDSYS-KJ-2018-007); 甘肃中医药大学引进人才科研启动基金项目(编号：2016YJRC-03); 甘肃省科技计划项目(编号：23CXNA0033)
2024-04-22
2024-04-22
2024-04-22